{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:58:16Z","timestamp":1758794296176,"version":"3.44.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Program for young scientists of the LMU Munich"},{"name":"Munich Clinician-Scientist Program"},{"DOI":"10.13039\/501100007537","name":"Freie Universit\u00e4t Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007537","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s15010-025-02504-0","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T02:42:30Z","timestamp":1745548950000},"page":"1819-1831","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Model-informed identification of optimised dosing strategies for meropenem in critically ill patients receiving SLEDD: an observational study"],"prefix":"10.1007","volume":"53","author":[{"given":"Franz","family":"Weber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Scharf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda B. S.","family":"Aulin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdinand","family":"Weinelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Paal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"Mikus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Vogeser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Habler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilhelm","family":"Huisinga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Zoller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Michelet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Kloft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Liebchen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"issue":"1","key":"2504_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13613-018-0467-6","volume":"8","author":"AS Truche","year":"2018","unstructured":"Truche AS, Ragey SP, Souweine B, Bailly S, Zafrani L, Bouadma L, et al. ICU survival and need of renal replacement therapy with respect to AKI duration in critically ill patients. Ann Intensive Care. 2018;8(1):1\u201311. https:\/\/doi.org\/10.1186\/s13613-018-0467-6.","journal-title":"Ann Intensive Care"},{"issue":"4","key":"2504_CR2","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4):S117-314.","journal-title":"Kidney Int"},{"issue":"6","key":"2504_CR3","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","volume":"14","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14(6):498\u2013509.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"2504_CR4","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4103\/0972-5229.45078","volume":"12","author":"J Chacko","year":"2008","unstructured":"Chacko J. Renal replacement therapy in the intensive care unit. Indian J Crit Care Med. 2008;12(4):174.","journal-title":"Indian J Crit Care Med."},{"issue":"12","key":"2504_CR5","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1007\/s00134-016-4504-3","volume":"42","author":"SepNet Critical Care Trials Group","year":"2016","unstructured":"SepNet Critical Care Trials Group. Incidence of severe sepsis and septic shock in German intensive care units: the prospective, multicentre INSEP study. Intensive Care Med. 2016;42(12):1980\u20139. https:\/\/doi.org\/10.1007\/s00134-016-4504-3.","journal-title":"Intensive Care Med"},{"issue":"1","key":"2504_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13054-019-2478-6","volume":"23","author":"JL Vincent","year":"2019","unstructured":"Vincent JL, Jones G, David S, Olariu E, Cadwell KK. Frequency and mortality of septic shock in Europe and North America: a systematic review and meta-analysis. Crit Care. 2019;23(1):1\u201311. https:\/\/doi.org\/10.1186\/s13054-019-2478-6.","journal-title":"Crit Care"},{"issue":"2","key":"2504_CR7","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/01.CCM.0000194725.48928.3A","volume":"34","author":"JL Vincent","year":"2006","unstructured":"Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34(2):344\u201353.","journal-title":"Crit Care Med"},{"issue":"1","key":"2504_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13054-018-1940-1","volume":"22","author":"S Braune","year":"2018","unstructured":"Braune S, K\u00f6nig C, Roberts JA, Nierhaus A, Steinmetz O, Baehr M, et al. Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: A population pharmacokinetic study. Crit Care. 2018;22(1):25.","journal-title":"Crit Care"},{"issue":"11","key":"2504_CR9","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","volume":"47","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181\u2013247. https:\/\/doi.org\/10.1007\/s00134-021-06506-y.","journal-title":"Intensive Care Med"},{"issue":"3","key":"2504_CR10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/antibiotics9030131","volume":"9","author":"C Scharf","year":"2020","unstructured":"Scharf C, Paal M, Schroeder I, Vogeser M, Draenert R, Irlbeck M, et al. Therapeutic drug monitoring of meropenem and piperacillin in critical illness\u2014experience and recommendations from one year in routine clinical practice. Antibiotics. 2020;9(3):131.","journal-title":"Antibiotics"},{"issue":"Supplement 2","key":"2504_CR11","doi-asserted-by":"publisher","first-page":"S266","DOI":"10.1093\/clinids\/24.Supplement_2.S266","volume":"24","author":"WA Craig","year":"1997","unstructured":"Craig WA. The pharmacology of meropenem, a new carbapenem antibiotic. Clin Infect Dis. 1997;24(Supplement 2):S266\u201375.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2504_CR12","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1093\/jac\/dkx209","volume":"72","author":"S Imani","year":"2017","unstructured":"Imani S, Buscher H, Marriott D, Gentili S, Sandaradura I. Too much of a good thing: a retrospective study of \u03b2-lactam concentration-toxicity relationships. J Antimicrob Chemother. 2017;72(10):2891\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"2504_CR13","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2165\/00003495-200868060-00006","volume":"68","author":"CM Baldwin","year":"2008","unstructured":"Baldwin CM, Lyseng-Williamson KA, Keam SJ. Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs. 2008;68(6):803\u201338.","journal-title":"Drugs"},{"issue":"1","key":"2504_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13054-019-2378-9","volume":"23","author":"R Guilhaumou","year":"2019","unstructured":"Guilhaumou R, Benaboud S, Bennis Y, Dahyot-Fizelier C, Dailly E, Gandia P, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients\u2014guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique\u2014SFPT) and the French Society of Anaesthesia and R\u00e9animation\u2014SFAR). Crit Care. 2019;23(1):1\u201320. https:\/\/doi.org\/10.1186\/s13054-019-2378-9.","journal-title":"Crit Care"},{"issue":"67","key":"2504_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jcrc.2021.09.011","volume":"1","author":"U Liebchen","year":"2022","unstructured":"Liebchen U, Paal M, Bucher V, Vogeser M, Irlbeck M, Schroeder I, et al. Trough concentrations of meropenem and piperacillin during slow extended dialysis in critically ill patients with intermittent and continuous infusion: a prospective observational study. J Crit Care. 2022;1(67):26\u201332.","journal-title":"J Crit Care"},{"issue":"2","key":"2504_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00228-019-02792-0","volume":"76","author":"S Donnellan","year":"2020","unstructured":"Donnellan S, Wright DFB, Roberts JA, Duffull SB, Schollum JBW, Putt TL, et al. The pharmacokinetics of meropenem and piperacillin-tazobactam during sustained low efficiency haemodiafiltration (SLED-HDF). Eur J Clin Pharmacol. 2020;76(2):239\u201347. https:\/\/doi.org\/10.1007\/s00228-019-02792-0.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"2504_CR17","doi-asserted-by":"publisher","first-page":"e0157923","DOI":"10.1128\/aac.01579-23","volume":"68","author":"JQ Hudson","year":"2024","unstructured":"Hudson JQ, Hilgers MN, Gosmanova EO. Removal of common antimicrobial agents by sustained low-efficiency dialysis. Antimicrob Agents Chemother. 2024;68(3):e0157923. https:\/\/doi.org\/10.1128\/aac.01579-23.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2504_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/pharmacy8010033","volume":"8","author":"P Brown","year":"2020","unstructured":"Brown P, Battistella M. Principles of drug dosing in sustained low efficiency dialysis (SLED) and review of antimicrobial dosing literature. Pharmacy. 2020;8(1):33.","journal-title":"Pharmacy"},{"issue":"11","key":"2504_CR19","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1111\/bcp.14846","volume":"87","author":"I Westermann","year":"2021","unstructured":"Westermann I, Gastine S, M\u00fcller C, Rudolph W, Peters F, Bloos F, et al. Population pharmacokinetics and probability of target attainment in patients with sepsis under renal replacement therapy receiving continuous infusion of meropenem: Sustained low-efficiency dialysis and continuous veno-venous haemodialysis. Br J Clin Pharmacol. 2021;87(11):4293\u2013303. https:\/\/doi.org\/10.1111\/bcp.14846.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2504_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/cpt.2049","volume":"109","author":"F Kluwe","year":"2021","unstructured":"Kluwe F, Michelet R, Mueller-Schoell A, Maier C, Klopp-Schulze L, van Dyk M, et al. Perspectives on model-informed precision dosing in the digital health era: challenges, opportunities, and recommendations. Clin Pharmacol Ther. 2021;109(1):29\u201336.","journal-title":"Clin Pharmacol Ther"},{"issue":"152","key":"2504_CR21","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jpba.2018.01.031","volume":"15","author":"M Paal","year":"2018","unstructured":"Paal M, Zoller M, Schuster C, Vogeser M, Sch\u00fctze G. Simultaneous quantification of cefepime, meropenem, ciprofloxacin, moxifloxacin, linezolid and piperacillin in human serum using an isotope-dilution HPLC\u2013MS\/MS method. J Pharm Biomed Anal. 2018;15(152):102\u201310.","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"2504_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/00005373-200208000-00013","volume":"53","author":"RA Cherry","year":"2002","unstructured":"Cherry RA, Eachempati SR, Hydo L, Barie PS. Accuracy of short-duration creatinine clearance determinations in predicting 24-hour creatinine clearance in critically ill and injured patients. J Trauma. 2002;53(2):267\u201371.","journal-title":"J Trauma"},{"issue":"2","key":"2504_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/j.1875-9114.1993.tb02698.x","volume":"13","author":"MB O\u2019Connell","year":"1993","unstructured":"O\u2019Connell MB, Wong MO, Bannick-Mohrland SD, Dwinell AM. Accuracy of 2- and 8-hour urine collections for measuring creatinine clearance in the hospitalized elderly. Pharmacother J Hum Pharmacol Drug Ther. 1993;13(2):135\u201342. https:\/\/doi.org\/10.1002\/j.1875-9114.1993.tb02698.x.","journal-title":"Pharmacother J Hum Pharmacol Drug Ther."},{"issue":"3","key":"2504_CR24","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10928-020-09682-4","volume":"47","author":"A Broeker","year":"2020","unstructured":"Broeker A, Wicha SG. Assessing parameter uncertainty in small-n pharmacometric analyses: value of the log-likelihood profiling-based sampling importance resampling (LLP-SIR) technique. J Pharmacokinet Pharmacodyn. 2020;47(3):219\u201328. https:\/\/doi.org\/10.1007\/s10928-020-09682-4.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2504_CR25","unstructured":"European Committee on Antimicrobial Susceptibility Testing(EUCAST). European Committee on antimicrobial susceptibility testing. 2022. EUCAST: clinical breakpoints and dosing of antibiotics. https:\/\/www.eucast.org\/clinical_breakpoints."},{"key":"2504_CR26","unstructured":"European Medicines Agency. Committee for medicinal products for human use (CHMP) guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products [Internet]. 2016. www.ema.europa.eu\/contact."},{"issue":"7","key":"2504_CR27","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1128\/AAC.36.7.1532","volume":"36","author":"BA Christensson","year":"1992","unstructured":"Christensson BA, Nilsson-Ehle I, Hutchison M, Haworth SJ, Oqvist B, Norrby SR. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob Agents Chemother. 1992;36(7):1532\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2504_CR28","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1128\/AAC.37.2.229","volume":"37","author":"M Chimata","year":"1993","unstructured":"Chimata M, Nagase M, Suzuki Y, Shimomura M, Kakuta S. Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease. Antimicrob Agents Chemother. 1993;37(2):229\u201333.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2504_CR29","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2165\/00003088-199528040-00002","volume":"28","author":"JW Mouton","year":"1995","unstructured":"Mouton JW, van den Anker JN. Meropenem clinical pharmacokinetics. Clin Pharmacokinet. 1995;28(4):275\u201386. https:\/\/doi.org\/10.2165\/00003088-199528040-00002.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"2504_CR30","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/jcph.812","volume":"57","author":"EK Chung","year":"2017","unstructured":"Chung EK, Cheatham SC, Fleming MR, Healy DP, Kays MB. Population pharmacokinetics and pharmacodynamics of meropenem in nonobese, obese, and morbidly obese patients. J Clin Pharmacol. 2017;57(3):356\u201368. https:\/\/doi.org\/10.1002\/jcph.812.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"2504_CR31","doi-asserted-by":"publisher","first-page":"5520","DOI":"10.1128\/AAC.00712-15","volume":"59","author":"M Ulldemolins","year":"2015","unstructured":"Ulldemolins M, Soy D, Llaurado-Serra M, Vaquer S, Castro P, Rodr\u00edguez AH, et al. Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements. Antimicrob Agents Chemother. 2015;59(9):5520\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"13","key":"2504_CR32","first-page":"1044","volume":"18","author":"N Yang","year":"2022","unstructured":"Yang N, Wang J, Xie Y, Ding J, Wu C, Liu J, et al. External evaluation of population pharmacokinetic models to inform precision dosing of meropenem in critically ill patients. Front Pharmacol. 2022;18(13):1044.","journal-title":"Front Pharmacol"},{"issue":"3","key":"2504_CR33","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ijantimicag.2019.06.016","volume":"54","author":"L Ehmann","year":"2019","unstructured":"Ehmann L, Zoller M, Minichmayr IK, Scharf C, Huisinga W, Zander J, et al. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic\/pharmacodynamic analysis. Int J Antimicrob Agents. 2019;54(3):309\u201317.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"2504_CR34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0924-8579(01)00474-5","volume":"19","author":"R Kitzes-Cohen","year":"2002","unstructured":"Kitzes-Cohen R, Farin D, Piva G, De Myttenaere-Bursztein SA. Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. Int J Antimicrob Agents. 2002;19(2):105\u201310.","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"2504_CR35","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.3390\/microorganisms9071505","volume":"9","author":"C Roger","year":"2021","unstructured":"Roger C, Louart B. Beta-lactams toxicity in the intensive care unit: an underestimated collateral damage? Microorganisms. 2021;9(7):1505.","journal-title":"Microorganisms."},{"issue":"4","key":"2504_CR36","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/cpt.2202","volume":"109","author":"SG Wicha","year":"2021","unstructured":"Wicha SG, M\u00e4rtson A, Nielsen EI, Koch BCP, Friberg LE, Alffenaar J, et al. From therapeutic drug monitoring to model-informed precision dosing for antibiotics. Clin Pharmacol Ther. 2021;109(4):928\u201341. https:\/\/doi.org\/10.1002\/cpt.2202.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"2504_CR37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/psp4.12492","volume":"9","author":"C Maier","year":"2020","unstructured":"Maier C, Hartung N, de Wiljes J, Kloft C, Huisinga W. Bayesian data assimilation to support informed decision making in individualized chemotherapy. CPT Pharmacometr Syst Pharmacol. 2020;9(3):153\u201364. https:\/\/doi.org\/10.1002\/psp4.12492.","journal-title":"CPT Pharmacometr Syst Pharmacol."},{"issue":"12","key":"2504_CR38","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.3390\/pharmaceutics13122128","volume":"13","author":"FA Weinelt","year":"2021","unstructured":"Weinelt FA, Stegemann MS, Theloe A, Pf\u00e4fflin F, Achterberg S, Schmitt L, et al. Development of a model-informed dosing tool to optimise initial antibiotic dosing\u2014a translational example for intensive care units. Pharmaceutics. 2021;13(12):2128. https:\/\/doi.org\/10.3390\/pharmaceutics13122128.","journal-title":"Pharmaceutics"},{"issue":"1","key":"2504_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13054-017-1829-4","volume":"21","author":"L Ehmann","year":"2017","unstructured":"Ehmann L, Zoller M, Minichmayr IK, Scharf C, Maier B, Schmitt MV, et al. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study. Crit Care. 2017;21(1):1\u201314. https:\/\/doi.org\/10.1186\/s13054-017-1829-4.","journal-title":"Crit Care"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02504-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-025-02504-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02504-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:40:59Z","timestamp":1758721259000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-025-02504-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2504"],"URL":"https:\/\/doi.org\/10.1007\/s15010-025-02504-0","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"type":"print","value":"0300-8126"},{"type":"electronic","value":"1439-0973"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Franz Weber (FWb): no competing interest. Christina Scharf (CS): CS received speaker honoraria from CytoSorbents Europe GmbH. Linda Brita Sofia Aulin (LA): no competing interest. Ferdinand Weinelt (FWe): no competing interest. Michael Paal (MP): no competing interest. Gerd Mikus (GM): no competing interest. Michael Vogeser (MV): no competing interest. Katharina Habler (KH): no competing interest. Wilhelm Huisinga (WH): WH received research grants from an industry consortium (AbbVie Deutschland GmbH & Co. K.G., AstraZeneca, Boehringer Ingelheim Pharma GmbH & Co. KG., F. Hoffmann-La Roche Ltd., Merck KGaA, Novo Nordisk A\/S and Sanofi) for the graduate research training program PharMetrX. Michael Zoller (MZ): MZ received research support from CytoSorbents Europe GmbH, consulting fees from Gilead and speaker honoraria from MSD. Robin Michelet (RM): no competing interest. Charlotte Kloft (CK): CK received research grants from an industry consortium (AbbVie Deutschland GmbH & Co. K.G., AstraZeneca, Boehringer Ingelheim Pharma GmbH & Co. KG., F. Hoffmann-La Roche Ltd., Merck KGaA, Novo Nordisk A\/S and Sanofi) for the graduate research training program PharMetrX, from the Innovative Medicines Initiative-Joint Undertaking (\u201cDDMoRe\u201d), from H2020-EU.3.1.3 (\u201cFAIR\u201d), Diurnal Ltd. and the Federal Ministry of Education and Research within the Joint Programming Initiative on Antimicrobial Resistance Initiative (\u201cJPIAMR\u201d), all outside the submitted work. Uwe Liebchen (UL): UL received consulting honoraria from CytoSorbents Europe GmbH and Medows S\u00e0rl, and was part of an advisory board of Roche Diagnostics International Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval and consent were obtained from the Institutional Review Board of the Medical Faculty of the Ludwig-Maximilians-University Munich, Germany (registration number 18-578).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}